Published in J Virol on August 01, 2005
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol (2009) 2.95
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J Virol (2006) 2.63
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature (2011) 2.26
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J Virol (2007) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Viral avoidance and exploitation of the ubiquitin system. Nat Cell Biol (2009) 1.77
The role of ubiquitylation in immune defence and pathogen evasion. Nat Rev Immunol (2011) 1.76
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J Biol Chem (2008) 1.68
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J Virol (2007) 1.51
APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms. J Virol (2010) 1.40
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J Virol (2008) 1.37
Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins. J Virol (2008) 1.37
Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J Biol Chem (2010) 1.36
Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol (2008) 1.36
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology (2007) 1.33
APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. J Virol (2006) 1.26
Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends Pharmacol Sci (2009) 1.24
Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet (2007) 1.23
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J Virol (2010) 1.20
Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J Biol Chem (2006) 1.19
The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles. J Virol (2006) 1.17
Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J Virol (2007) 1.13
Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One (2012) 1.12
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
APOBEC3G expression is dysregulated in primary HIV-1 infection and polymorphic variants influence CD4+ T-cell counts and plasma viral load. AIDS (2010) 1.08
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
The Role of Elongin BC-Containing Ubiquitin Ligases. Front Oncol (2012) 1.04
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and ElonginC. J Virol (2012) 1.01
HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res (2009) 1.00
APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathog (2008) 0.99
Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology (2008) 0.99
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology (2006) 0.92
N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J Virol (2011) 0.91
On the solution conformation and dynamics of the HIV-1 viral infectivity factor. J Mol Biol (2011) 0.91
Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression. PLoS One (2011) 0.91
Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Res (2010) 0.90
Identifying determinants of cullin binding specificity among the three functionally different Drosophila melanogaster Roc proteins via domain swapping. PLoS One (2008) 0.90
Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother (2009) 0.89
Elevated hypermutation levels in HIV-1 natural viral suppressors. Virology (2013) 0.88
Interactions between HIV-1 Vif and human ElonginB-ElonginC are important for CBF-β binding to Vif. Retrovirology (2013) 0.88
Polyubiquitination of APOBEC3G is essential for its degradation by HIV-1 Vif. J Virol (2010) 0.88
Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J Virol (2010) 0.87
Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif. J Biol Chem (2010) 0.86
Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein. Viruses (2012) 0.85
Dispersed and conserved hydrophobic residues of HIV-1 Vif are essential for CBFβ recruitment and A3G suppression. J Virol (2013) 0.85
Identification of a novel HIV-1 inhibitor targeting Vif-dependent degradation of human APOBEC3G protein. J Biol Chem (2015) 0.81
APOBEC3G impairs the multimerization of the HIV-1 Vif protein in living cells. J Virol (2013) 0.81
HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. Virology (2012) 0.80
Requirement of HIV-1 Vif C-terminus for Vif-CBF-β interaction and assembly of CUL5-containing E3 ligase. BMC Microbiol (2014) 0.80
HIV-1 Vpr Protein Induces Proteasomal Degradation of Chromatin-associated Class I HDACs to Overcome Latent Infection of Macrophages. J Biol Chem (2015) 0.77
Towards Inhibition of Vif-APOBEC3G Interaction: Which Protein to Target? Adv Virol (2010) 0.75
The role of cullin 5-containing ubiquitin ligases. Cell Div (2016) 0.75
Role of APOBEC3F Gene Variation in HIV-1 Disease Progression and Pneumocystis Pneumonia. PLoS Genet (2016) 0.75
Real time quantitative PCR. Genome Res (1996) 35.79
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol (1999) 9.54
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol (2004) 6.51
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science (2003) 6.20
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J (2004) 5.67
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem (2003) 5.45
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol (2004) 5.35
Inhibition of hepatitis B virus replication by APOBEC3G. Science (2004) 5.15
Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr Biol (2004) 4.89
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev (1998) 4.29
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci U S A (2004) 3.73
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A (2004) 3.60
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev (2004) 3.28
Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology (1997) 3.21
Ubiquitin-dependent degradation of multiple F-box proteins by an autocatalytic mechanism. Proc Natl Acad Sci U S A (1999) 3.17
Ubiquitination and degradation of the substrate recognition subunits of SCF ubiquitin-protein ligases. Mol Cell (1998) 3.12
Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J (2004) 3.07
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem (2004) 2.79
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res (2004) 2.28
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A (2002) 1.61
Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol (2004) 1.46
The abundance of cell cycle regulatory protein Cdc4p is controlled by interactions between its F box and Skp1p. Mol Cell Biol (1999) 1.36
Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect (2004) 1.13
Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. J Biol Chem (2004) 1.05
The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin. Biochem Biophys Res Commun (2004) 0.95
Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol (2004) 0.86
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
Validation of the ITS2 region as a novel DNA barcode for identifying medicinal plant species. PLoS One (2010) 5.39
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev (2004) 3.39
Use of ITS2 region as the universal DNA barcode for plants and animals. PLoS One (2010) 2.92
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J Virol (2007) 2.47
Ultrahard nanotwinned cubic boron nitride. Nature (2013) 2.44
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc Natl Acad Sci U S A (2005) 2.42
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction. Nature (2011) 2.26
Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. Int J Epidemiol (2004) 2.19
Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med (2003) 2.17
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J Virol (2006) 2.16
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol (2007) 1.91
Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res (2008) 1.91
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology (2006) 1.86
Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol (2008) 1.86
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol (2008) 1.83
DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest. J Virol (2007) 1.77
First snapshots of the HIV-1 RNA structure in infected cells and in virions. J Biol Chem (2004) 1.76
Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res (2010) 1.74
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J (2006) 1.64
Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis (2002) 1.62
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol (2008) 1.57
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J Virol (2007) 1.53
Coinfection with HIV and hepatitis C virus among injection drug users in southern China. Clin Infect Dis (2005) 1.52
Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase. Nat Commun (2013) 1.50
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J (2008) 1.39
A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J Virol (2009) 1.38
Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol (2008) 1.38
A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J Virol (2009) 1.36
Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr (2005) 1.33
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci U S A (2009) 1.29
Characterization of a novel Cullin5 binding domain in HIV-1 Vif. J Mol Biol (2007) 1.27
Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope. Virology (2004) 1.26
STAT1-independent cell type-specific regulation of antiviral APOBEC3G by IFN-alpha. J Immunol (2006) 1.25
Characterization of full-length enterovirus 71 strains from severe and mild disease patients in northeastern China. PLoS One (2012) 1.24
Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J Mol Biol (2007) 1.23
Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS One (2008) 1.23
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma. Hepatology (2007) 1.18
Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutières syndrome-related SAMHD1. Cell Rep (2013) 1.18
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol (2006) 1.18
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res (2011) 1.16
High prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in China. PLoS One (2010) 1.15
Circulating coxsackievirus A16 identified as recombinant type A human enterovirus, China. Emerg Infect Dis (2011) 1.15
A novel DCAF1-binding motif required for Vpx-mediated degradation of nuclear SAMHD1 and Vpr-induced G2 arrest. Cell Microbiol (2012) 1.13
Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase components. PLoS One (2012) 1.12
Adenovirus E4orf6 assembles with Cullin5-ElonginB-ElonginC E3 ubiquitin ligase through an HIV/SIV Vif-like BC-box to regulate p53. FASEB J (2007) 1.06
Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res (2005) 1.05
Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression. Cell Microbiol (2007) 1.04
Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol (2005) 1.01
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol (2005) 1.00
Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res (2007) 0.99
Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J Virol (2012) 0.99
Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology (2008) 0.99
Selection in context: patterns of natural selection in the glycoprotein 120 region of human immunodeficiency virus 1 within infected individuals. Genetics (2004) 0.99
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer (2011) 0.97
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases. Cell Microbiol (2008) 0.97
Identification of critical regions in human SAMHD1 required for nuclear localization and Vpx-mediated degradation. PLoS One (2013) 0.96
Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res (2011) 0.95
Host restriction of HIV-1 by APOBEC3 and viral evasion through Vif. Curr Top Microbiol Immunol (2009) 0.93
TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells. J Immunol (2008) 0.93
Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol (2014) 0.93
Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One (2010) 0.92
Cell-specific regulation of APOBEC3F by interferons. Acta Biochim Biophys Sin (Shanghai) (2007) 0.92
The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology (2006) 0.92
Reduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities. PLoS One (2012) 0.92
Core binding factor beta plays a critical role by facilitating the assembly of the Vif-cullin 5 E3 ubiquitin ligase. J Virol (2014) 0.92
Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes. J Gen Virol (2008) 0.91
IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochem Biophys Res Commun (2004) 0.89
Species identification of medicinal pteridophytes by a DNA barcode marker, the chloroplast psbA-trnH intergenic region. Biol Pharm Bull (2010) 0.89
The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users. J Acquir Immune Defic Syndr (2005) 0.88
Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China. World J Gastroenterol (2008) 0.87
Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions. J Virol (2010) 0.87